Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere
- 1 January 1996
- journal article
- review article
- Published by Wiley in Biopolymers
- Vol. 40 (2) , 235-244
- https://doi.org/10.1002/(sici)1097-0282(1996)40:2<235::aid-bip3>3.0.co;2-x
Abstract
The human immunodeficiency virus (HIV) codes for an aspartic protease known to be essential for retroviral maturation and replication. The HIV protease can recognize Phe-Pro and Tyr-Pro sequences as the virus-specific cleavage site. These features provided a basis for the rational design of selective HIV protease-targeted drugs for the treatment of acquired immunodeficiency syndrome (AIDS). HIV protease is formed from two identical 99 amino acid peptides. We replaced the two Cys residues by L-Ala to synthesize [Ala67,95]-HIV-I protease by the solid phase method and then prepared [Tyr6,42, Nle36,46,(NHCH2COSCH2CO)51–52, Ala67,95]HIV-I protease (NY-5 isolate) using the thioester chemical ligation method. Based on the substrate transition state, we designed and synthesized a novel class of HIV protease inhibitors containing an unnatural amino acid, (2S, 3S)-3-amino-2-hydroxy-4-phenylbutyric acid, named allophenylnorstatine (Apns) with a hydroxymethylcarbonyl (HMC) isostere. Among them, the conformationally constrained tripeptide kynostatin (KNI)-272 (iQoa-Mta-Apns-Thz-NHBut) was a highly selective and superpotent HIV protease inhibitor (Ki = 0.0055 nM). KNI-272 exhibited potent antiviral activities against both AZT-sensitive and -insensitive clinical HIV-1 isolates as well as HIV-2 with low cytotoxicity. After i.d. administration, bioavailability of KNI-272 was 42.3% in rats. Also, KNI-272 exhibited in vivo anti-HIV activities in human PBMC-SCID mice. The x-ray crystallography and molecular modeling studies showed that the HMC group in KNI-272 interacted excellently with the aspartic acid carboxyl groups of HIV protease active site in the essentially same hydrogen-bonding mode as the transition state. This result implies that the HMC isostere is an ideal transition-state mimic and contributes to the high activity of KNI-272. © 1996 John Wiley & Sons, Inc.Keywords
This publication has 22 references indexed in Scilit:
- Solution Structure of HIV-1 Protease-Allophenylnorstatine Derivative Inhibitor Complex Obtained from Molecular Dynamics Simulation.CHEMICAL & PHARMACEUTICAL BULLETIN, 1994
- Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-aids drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrationsBiopharmaceutics & Drug Disposition, 1993
- Pharmacokinetic study of a tripeptide HIV‐1 protease inhibitor, KNI‐174, in rats after intravenous and intraduodenal administrationsBiopharmaceutics & Drug Disposition, 1993
- Efficient solid phase peptide synthesisInternational Journal of Peptide and Protein Research, 1992
- Kynostatin (KNI-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.CHEMICAL & PHARMACEUTICAL BULLETIN, 1992
- Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modesJournal of Medicinal Chemistry, 1991
- KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic.CHEMICAL & PHARMACEUTICAL BULLETIN, 1991
- Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic.CHEMICAL & PHARMACEUTICAL BULLETIN, 1991
- Rational Design of Peptide-Based HIV Proteinase InhibitorsScience, 1990
- Peptide substrates and inhibitors of the HIV-1 proteaseBiochemical and Biophysical Research Communications, 1989